Cambridge-based Eutropics Pharmaceuticals signed a deal with the National Cancer Institute to develop its diagnostic assay for cancer treatments in patients with Acute Myelogenous Leukemia, (AML).

Through the Institute’s Small Business Initiative Research (SBIR) initative, a program designed to develop and commercialize technologies and products to prevent, diagnose, and treat cancer, the partnership enables further development of Eutropics’ proprietary BH3 profiling diagnostic assay for personalized medicine approaches in patient management of AML, a cancer of the blood and bone.